Healthcare Industry News: Bovie
News Release - July 22, 2009
Bovie Medical Corporation Announces 510(k) Submissions to the FDA for Its Seal-N-Cut Vessel Sealing InstrumentsMELVILLE, N.Y.--(HSMN NewsFeed)--Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced a 510K submission to the Food & Drug Administration seeking pre-market clearance for Bovie’s Polarian Seal-N-Cut(TM) vessel sealing line of hybrid monopolar and bipolar forceps.
The new Seal-N-Cut(TM) line of instruments provides for monopolar and bipolar energy combined with intelligent feedback from Bovie’s Hybrid VS electrosurgical generator.
Furthermore, the Seal-N-Cut(TM) devices accommodate a wide array of possible applications in either monopolar or bipolar surgeries thereby serving endoscopic needs in multiple endoscopic fields including Endo GYN, General Surgery, Pediatric surgery, Thoracic Endoscopy and Urology. Bipolar vessel sealing and coagulation is one of the fastest growing markets in Endoscopy, estimated to exceed $1 billion in revenues worldwide.
Andrew Makrides, president of Bovie Medical stated, “Vessel sealing during surgery especially in the field of gynecology has become a rapidly expanding growth market. The added features of our Seal-N-Cut(TM) instrumentation allows the Company to actively compete in this market.”
For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.Boviemedical.com.
This document may contain some forward looking statements, particularly regarding operational prospects in 2009 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company’s SEC filings.
Source: Bovie Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.